Idoxifene versus tamoxifen: A randomized comparison in postmenopausal patients with metastatic breast cancer

Annals of Oncology

Volumn 14, Issue 2, 2003, Pages 233-241

  Arpino, G ^a   Krishnan, M Nair ^b   Dinesh, C Doval ^c   Bardou, V J ^a   Clark, G M ^a   Elledge, R M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b REGIONAL CANCER CENTRE   (India)

^c Kidwai Memorial Institute   (India)

Author keywords

Advanced breast cancer; Clinical trial; Endocrine therapy; Hormone therapy; Idoxifene; Tamoxifen

Indexed keywords

HORMONE RECEPTOR; IDOXIFENE; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGE; AGED; ALLERGIC REACTION; ARTICLE; ASTHENIA; BREAST CANCER; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; ESTROGEN ACTIVITY; FACE EDEMA; FEMALE; FLUSHING; GASTROINTESTINAL TOXICITY; HEARING DISORDER; HEART DISEASE; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; HYPOTHYROIDISM; LIVER FAILURE; MAJOR CLINICAL STUDY; MYALGIA; PATHOLOGIC FRACTURE; PLEURA EFFUSION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; STOMATITIS; SURVIVAL RATE; THROMBOEMBOLISM; UTERUS DISEASE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POSTMENOPAUSE; SURVIVAL; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0345269296     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg097     Document Type: Article

References (43)

1. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993; 43: 7-26.
2. Jensen OM, Esteve J, Moller H, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990; 26: 1167-1256.
3. Osborne CK. Receptors. Philadelphia, PA: Lippincott 1991.
4. Litherland S, Jackson IM. Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 1988; 15: 183-194.
5. Henderson IC. Endocrine therapy of metastatic breast cancer. New York, NY: Lippincott 1991.
6. McCague R, Leclercq G, Legros N et al. Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. J Med Chem 1989; 32: 2527-2533.
7. Chander SK, McCague R, Luqmani Y et al. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res 1991; 51: 5851-5858.
8. Young H, Carnochan P, Trivedi M et al. Pharmacokinetics and biodistribution of radiolabelled idoxifene: prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapy. Nucl Med Biol 1995; 22: 405-411.
9. McCague R, Parr IB, Haynes BP. Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites. Biochem Pharmacol 1990; 40: 2277-2283.
10. Johnston SR, Boeddinghaus IM, Riddler S et al. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Cancer Res 1999; 59: 3646-3651.
11. Nuttall ME, Bradbeer JN, Stroup GB et al. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Endocrinology 1998; 139: 5224-5234.
12. Johnston SR, Riddler S, Haynes BP et al. The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. Br J Cancer 1997; 75: 804-809.
13. Pace P, Jarman M, Phillips D et al. Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts. Br J Cancer 1997; 76: 700-704.
14. Osborne MR, Hewer A, Davis W et al. Idoxifene derivatives are less reactive to DNA than tamoxifen derivatives, both chemically and in human and rat liver cells. Carcinogenesis 1999; 20: 293-297.
15. Coombes RC, Haynes BP, Dowsett M et al. Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Res 1995; 55: 1070-1074.
16. Johnston SRD, Gumbrell L, Evan TRJ et al. A phase II randomized double-blind study of idoxifene (40 mg/d) versus tamoxifen (40 mg/d) in patients with locally advanced metastatic breast cancer resistant to tamoxifen (20 mg/d). Proc Am Soc Clin Oncol 1999; 18: 109a.
17. Dowsett M, Dixon JM, Horgan K et al. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin Cancer Res 2000; 6: 2260-2267.
18. Kaplan EL, Meier P. Non-parametric estimation for incomplete observation. J Am Stat Assoc 1958; 53: 457-471.
19. Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A 1972; 135: 185-207.
20. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials 1984; 5: 348-361.
21. Mouridsen H, Palshof T, Patterson J, Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat Rev 1978; 5: 131-141.
22. Castiglione-Gertsch M, Pampallona S, Varini M et al. Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate? Ann Oncol 1993; 4: 735-740.
23. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
24. Collaborative EBCT. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15.
25. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
26. Jordan VC. Tamoxifen: the herald of a new era of preventive therapeutics. J Natl Cancer Inst 1997; 89: 747-749.
27. Powles TJ, Hardy JR, Ashley SE et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989; 60: 126-131.
28. Love RR. Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 1990; 82: 18-21.
29. Fisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 1989; 320: 479-484.
30. Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 1984; 68: 887-889.
31. Delmas PD, Garnero P, MacDonald B. Idoxifene reduces bone turnover in osteopenic postmenopausal women. Bone 1998; 23 (Suppl 1): S494 (Abstr F357).
32. Yue TL, Vickery-Clark L, Louden CS et al. Selective estrogen receptor modulator idoxifene inhibits smooth muscle cell proliferation, enhances re-endothelialization, and inhibits neointimal formation in vivo after vascular injury. Circulation 2000; 102: III281-III288.
33. Fornander T, Rutqvist LE, Cedermark B et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117-120.
34. Fisher B, Costantino JP, Redmond CK et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-537.
35. Fornander T, Hellstrom AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993; 85: 1850-1855.
36. Fleischer AC, Wheeler JE, Yeh IT et al. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J Ultrasound Med 1999; 18: 503-512.
37. Buzdar A, Hayes D, El-Khoudary A et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 2002; 73: 161-175.
38. Bruning PF. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer 1992; 28A: 1404-1407.
39. Gershanovich M, Garin A, Baltina D et al. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat 1997; 45: 251-262.
40. Wiseman LR, Goa KL. Toremifene: a review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs 1997; 54: 141-160.
41. Dhingra K. Antiestrogens-tamoxifen, SERMs and beyond. Invest New Drugs 1999; 17: 285-311.
42. Stenbygaard LE, Herrstedt J, Thomsen JF et al. Toremifene and tamoxifen in advanced breast cancer-a double-blind cross-over trial. Breast Cancer Res Treat 1993; 25: 57-63.
43. Johnston SRD, Gorbunova V, Lichinister M et al. A multicentre double blind randomised phase III trial of idoxifene versus tamoxifen as first line endocrine therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20: (Abstr 113a).